CTCBIO Inc
CTCBIO Inc. provides various pharmaceutical products in South Korea and internationally. The company offers animal and human pharmaceuticals; feed additives and ingredients; and functional food products. It also provides cardiovascular, gastrointestinal, osteoporosis, antibiotic, smoking cessation, antifungal and antiviral, antiepileptic, allergic rhinitis, dermatology and genito-urinory, allergi… Read more
CTCBIO Inc (060590) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.079x
Based on the latest financial reports, CTCBIO Inc (060590) has a cash flow conversion efficiency ratio of 0.079x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩5.64 Billion) by net assets (₩71.75 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
CTCBIO Inc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how CTCBIO Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
CTCBIO Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CTCBIO Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
RS Public Company Limited
BK:RS-R
|
-0.011x |
|
AS Tallinna Vesi
F:A1T
|
0.055x |
|
SDI Group plc
PINK:SDIIF
|
0.048x |
|
Muthoot Microfin Limited
NSE:MUTHOOTMF
|
0.138x |
|
Bank of Botetourt
PINK:BORTP
|
N/A |
|
Currency Exchange International Corp
PINK:CURN
|
-0.089x |
|
Hoang Quan Consulting Trading Service Real Estate Corp
VN:HQC
|
0.115x |
|
Patriot One Technologies Inc
F:0PL
|
-0.493x |
Annual Cash Flow Conversion Efficiency for CTCBIO Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of CTCBIO Inc from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩69.62 Billion | ₩4.50 Billion | 0.065x | -40.69% |
| 2023-12-31 | ₩75.44 Billion | ₩8.22 Billion | 0.109x | -42.66% |
| 2022-12-31 | ₩95.96 Billion | ₩18.22 Billion | 0.190x | +150.02% |
| 2021-12-31 | ₩85.01 Billion | ₩6.46 Billion | 0.076x | +1036.38% |
| 2020-12-31 | ₩76.32 Billion | ₩510.09 Million | 0.007x | -70.18% |
| 2019-12-31 | ₩74.74 Billion | ₩1.68 Billion | 0.022x | +178.74% |
| 2018-12-31 | ₩86.87 Billion | ₩-2.47 Billion | -0.028x | -813.17% |
| 2017-12-31 | ₩73.98 Billion | ₩295.30 Million | 0.004x | -94.71% |
| 2016-12-31 | ₩90.89 Billion | ₩6.86 Billion | 0.076x | +420.86% |
| 2015-12-31 | ₩99.14 Billion | ₩1.44 Billion | 0.014x | +456.42% |
| 2014-12-31 | ₩85.49 Billion | ₩-347.74 Million | -0.004x | -113.69% |
| 2013-12-31 | ₩92.23 Billion | ₩2.74 Billion | 0.030x | -- |